Granules India Q3 FY26: Navigating Complexity, Expanding Horizons

Granules India Limited has reported a robust performance for the third quarter of fiscal year 2026, demonstrating resilience and strategic execution amidst a dynamic pharmaceutical landscape. The company's consolidated revenue for Q3 FY26 stood at INR1,388 crore, marking a significant 22% year-on-year growth and a 7% sequential increase from Q2 FY26. This impressive top-line expansion was complemented by a strong improvement in profitability, with EBITDA reaching INR308.1 crore, a 34% surge compared to the same period last year. The EBITDA margin expanded by 196 basis points year-on-year to 22.2%, reflecting disciplined operational management and a favorable product mix. Profit After Tax (PAT) also saw a healthy rise of 28% year-on-year, closing the quarter at INR150.2 crore.

The growth narrative for Granules India in Q3 FY26 was primarily driven by its Finished Dosage (FD) segment, particularly in North America and Europe. The FD segment contributed INR1,055.7 crore to the total revenue, accounting for 76% of the overall sales. This segment's strong performance underscores the company's successful market penetration and increased sales from existing customers, alongside new product launches in Europe. While the Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) segments also contributed positively, the company's strategic focus on value-added finished dosages is clearly yielding results. The Peptide/CDMO segment, however, experienced a temporary EBITDA loss of INR24.8 crore in Q3 FY26, attributed to planned maintenance activities and higher operating costs. Management remains optimistic about this segment, anticipating a meaningful improvement in Q4 FY26 and aiming for positive EBITDA by the next financial year.

Strategic Imperatives and Operational Excellence

Granules India's strategic priorities are clearly defined: a transition towards higher complexity generics, normalization of operations at the Gagillapur facility, strengthening quality systems, expanding market presence, and scaling operations at its Genome Valley Life Sciences (GLS) facility. The company's complex generics portfolio is showing significant traction, with its contribution to total revenue growing from 27% in Q3 FY25 to 49% in Q3 FY26. This expansion is largely fueled by the scale-up of its ADHD portfolio in the US market. The company is also leveraging its R&D capabilities to develop differentiated products, including progress on TFA-free peptide chemistries for the cosmetics segment.

On the regulatory front, Granules India has made notable progress. The US FDA completed a GMP inspection at the company's US packaging facility with zero observations, a testament to its robust quality systems. Furthermore, the Gagillapur facility received ANVISA Brazil GMP certification, reinforcing improvements in its quality framework. Regarding the FDA warning letter for Gagillapur, management held a post-warning letter meeting in early January 2026 and is preparing to submit the requested documentation. The company has proactively de-risked by filing select products from its US and GLS facilities, ensuring business continuity.

Sustainability and Future Outlook

Granules India continues to embed sustainability into its core operations, achieving significant milestones in Q3 FY26. The company's CDP climate change rating improved to 'A' from 'B', and its S&P Corporate Sustainability Assessment (CSA) score rose to 62, placing it among the top 10% of global peers. The Gagillapur facility achieved zero waste to landfill, demonstrating platinum-plus waste diversion. These achievements underscore Granules' commitment to environmental stewardship and responsible business practices.

Financially, the company's Return on Capital Employed (ROCE) improved to 16.8% in Q3 FY26 from 16.2% in Q2 FY26, driven by enhanced operating profit. Cash flow from operations also saw a healthy increase to INR218.7 crore. Net debt slightly reduced to INR1,015.1 crore, and the cash-to-cash cycle improved to 202 days. The company's recent preferential issue, which received strong shareholder support, further strengthens its balance sheet, providing financial flexibility for capacity expansion and value-accretive opportunities. Granules India is poised for continued growth, with plans to launch at least one to two new products from its GLS facility in the next one to two quarters and a sustained focus on operational efficiencies and digitalization to enhance quality compliance and competitiveness.